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Aim: Cisplatin doublets are standard 1st line treatment for advanced non-small cell lung
cancer (NSCLC), without accurate predictor for response and survival, but important toxic-
ity. Our aims were to identify predictive (for response) and prognostic (for survival) biological
signatures in patients with NSCLC using messenger RNAs (mRNA) and miRNA expression.
Methods: Patients with pathologically proven untreated NSCLC, receiving 1st line
cisplatin–vinorelbine and with an assessable lesion were eligible. A bronchial biopsy was
lysed into Tripure Isolation Reagent on ice, snap frozen, and stored at −80°C. mRNA
expression was analyzed using microarrays Agilent Technologies. miRNA expression was
assessed using TaqMan Low Density Arrays (756 human miR panel, Applied Biosystems).
Validation was performed by RT-PCR on the selected genes. Survival was measured from
the registration date and response assessed by WHO criteria.
Results:Biopsies for transcriptomic analyses were obtained from 60 consecutive patients.
No statistically significant differences were observed according to the main clinical char-
acteristics, response rate (43 vs. 41%) or survival (median 25 vs. 29 months) between
derivation and validation sets. In the derivation set (n=38 patients), two mRNA and one
miRNA predictive signatures for response were obtained. One mRNA and one miRNA
prognostic signatures were derived from the first set, allowing an adequate distinction
of patients with good and poor overall and progression-free survivals. None of these
signatures could be validated in the validation set (n=22 patients).
Conclusion: In this prospective study with advanced NSCLC treated with cisplatin–
vinorelbine, we were able to derive with high throughput techniques predictive and
prognostic signatures based on transcriptomic analyses. However, these results could not
be reproduced in an independent validation set.The role of miRNA and mRNA as predictive
or prognostic factors remains a research topic and the use of high throughput technology
in that context questionable. The ClinicalTrials.gov study identifier is NCT00864266
(www.clinicaltrials.gov).
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INTRODUCTION
Presently, non-small cell lung cancer (NSCLC) is the first cause of
cancer death in industrialized countries. For most of the patients,
the prognosis is poor (1). A few prognostic factors have been con-
sistently reported in the literature, including performance status,
gender, stage, or histology (2) but no prognostic score is allowing
valid individual prognostic prediction. With a better understand-
ing of the tumor biology and the development of high throughput
techniques allowing multiple investigations on the same time,
multiple prognostic biological signatures, based on messenger
RNAs (mRNA) or miRNA analyses, have been proposed. How-
ever, most were constructed from retrospective studies, restricted
to limited stages and surgical cases (3). Nevertheless, more than
two-thirds of the patients are diagnosed at an advanced or metasta-
tic stage for which only palliative chemotherapy can be provided.
While the activity of first-line chemotherapy was demonstrated
in randomized trials and meta-analyses (4), only 20–40% of the
patients will exhibit an objective response. Customized therapy
based on targeted agents has shown its effectiveness in tumors pre-
senting with EGFR activating mutations (5) or ALK translocation
(6). However, for most patients, there are no reliable predictive fac-
tor assessing chemosensitivity. This explains why a large number
of patients are exposed uselessly to expensive and/or toxic drugs.
While retrospective studies suggested that biomarkers could be
helpful in predicting sensitivity to platinum derivatives (ERCC1
and XRCC1), taxanes (BRCA1), vincalcaloids (β tubulines), or
gemcitabine (RRM1), two randomized trials failed to demon-
strate that a genotypic approach based on ERCC1 or combined
ERCC1 and RRM1 can help in predicting chemosensitivity and
survival (7, 8).
The European Lung Cancer Working Party (ELCWP) initiated
a prospective study aiming to find biological signatures that would
predict response to chemotherapy and prognostic significance for
progression-free and overall survival in advanced and metasta-
tic NSCLC. First data of this study were previously published,
concerning the miRNA analyses performed on a homogeneous
derivation group of 38 patients treated with a same combina-
tion of cisplatin and vinorelbine. We were able to identify a
two-miRNA signature predicting response to this chemotherapy
regimen and a four-miRNA signature with prognostic value for
survival (9).
The current study presents the results of our prospective study
based on both mRNA and miRNA analyses and including the data
from the initial derivation cohort and a validation cohort.
MATERIALS AND METHODS
To be eligible for the study, patients had to meet the following
inclusion criteria: histologically confirmed NSCLC (generally, this
information was available after registration due to the design of the
protocol), to have a bronchial biopsy for biomarkers analysis, to be
a candidate for standard first-line chemotherapy. Other key eligi-
bility criteria were: age≥ 18 years; presence of a measurable lesion;
no prior chemotherapy; no history of cancer other than non-
melanoma skin cancer, in situ cervical cancer or cured malignancy
(interval> 5 years without recurrence). Signed informed consent
had to be obtained prior to registration. The ethics committees of
the participating institutions had approved the study protocol, in
accordance with current legislation. The ClinicalTrials.gov study
identifier is NCT00864266.
After registration at the ELCWP data center, biopsies and com-
plete tumoral work-up, a therapeutic choice was made by the
physician in charge of the patient. If the indication of chemother-
apy for NSCLC was confirmed, the choice of treatment was left
to the investigator, based on clinical practice guidelines of the
ELCWP (10), with a preferential option for the combination of
cisplatin (60 mg/m2 day 1) plus vinorelbine (25 mg/m2 days 1
and 8), every 3 weeks in order to obtain a homogeneous group
for biomarkers analysis. For the present analysis, the selected
group of patients required histologically confirmed NSCLC whose
response to chemotherapy with cisplatin–vinorelbine was evalu-
able according to WHO criteria (11) and adequate biopsy obtained
for transcriptomic analysis. Evaluation of response was performed
every three cycles and in case of objective response, patients were
treated until best response. All charts were reviewed during regu-
lar meetings by at least three independent ELCWP investigators.
Patients with early progression or death due to malignant disease
prior to evaluation or toxicity and treatment cessation due to tox-
icity were considered as treatment failures. Survival was measured
from the registration date until death from any cause or last date
known to be alive. Progression-free survival was measured from
date of registration until date of first progression or death.
BIOPSY PROCEDURE
The procedure for collecting and processing bronchial biopsies
was standardized. Any patient with pulmonary lesion consistent
with the diagnosis of lung cancer and for which bronchoscopy
was considered, was offered the protocol before any treatment has
been applied. The sequence of diagnostic bronchoscopy was iden-
tical to a standard one, with the exception of additional samples
for the study. A minimum of two tumoral biopsies were collected
if the tumor was accessible during endoscopy. For each tumor
biopsy, a control sample was taken in a macroscopically healthy
bronchial area, remote from the tumor. Among the biopsies, the
first sample was fixed in formalin and embedded in paraffin for his-
tological diagnosis. The second one was treated for transcriptomic
analyses (mRNA and miRNA) by high throughput techniques. It
was directly lysed in Tripure (Roche Diagnostics, Indianapolis, IN,
USA) on ice and snap frozen with liquid nitrogen. If possible, a
third series of biopsies was collected and directly frozen in liquid
nitrogen in order to store it in a tissue bank for further molecular
biology analyses. Both series of biopsies collected for molecular
biology were stored at−80°C.
NUCLEIC ACID ISOLATION
This procedure allowed isolation of total RNA for both mRNAs
and miRNAs expression analyses. RNA isolation was performed
using the Tripure reagent (Roche Diagnostics). We added 20µg
of glycogen (Roche Diagnostics) as carrier and the separation
between the organic and the aqueous phases was achieved on
Phase Lock Gel (Eppendorf, Hamburg, Germany), optimizing the
recovery of nucleic acids. RNA was assessed for quantity and purity
on the NanoDrop ND-1000 spectrophotometer (NanoDrop Tech-
nologies, Rockland, DE, USA) and for integrity on the Agilent 2100
bioanalyser with RNA 6000 NanoAssay (Agilent Technologies,Palo
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Alto, CA, USA). The extracted RNAs were stored at −80°C. The
RNA was used to assess expression of the mRNAs using microar-
rays (Agilent Technologies) and of the miRNAs by Taqman Low
Density arrays (Applied Biosystem).
MESSENGER RNAS EXPRESSION ANALYSIS (MICROARRAYS)
Messenger RNAs were reverse-transcribed by using a T7 primer
coupled with oligo-dT primers and Moloney murine leukemia
virus-reverse transcriptase (MMLV-RT). The cDNAs were then
in vitro transcribed into labeled cRNA by the T7 RNA poly-
merase with fluorescent nucleotides, Cy5 for samples or Cy3 for
reference RNA dyes, by using the Low input RNA Fluorescent Lin-
ear Amplification Plus kit (Agilent Technologies). RNAs spike-in
(Agilent Technologies) served as positive controls to monitor the
whole microarray workflow (sample amplification, labeling and
microarray processing). An amount of 100 ng of starting total
RNA was engaged for each sample and 100 ng of pooled refer-
ence RNAs was amplified in parallel in the same experiment with
the same Master-Mix. Labeled cRNA was checked for quantity
and dye incorporation by the NanoDrop ND-1000 spectropho-
tometer (NanoDrop Technologies) and the Gaussian distribution
of sample sizes was assessed by migration profiles on the Agilent
2100 bioanalyser with RNA 6000 NanoAssay (Agilent Technolo-
gies). Thereafter, the labeled cRNAs was hybridized on an Agilent
oligonucleotide microarray (Two Colors Whole Human Genome
4× 44 K arrays,Agilent Technologies) for 17 h at 65°C in a rotating
oven according to the provider’s protocol (Agilent Technologies).
After disassembling the hybridization chambers, the slides were
washed and the signal was read by confocal laser scanning (Agi-
lent Technologies). Grid positioning, spots localization, outliers
flagging, fluorescence intensities quantification, background level
assessment, and correction of the values according to the back-
ground followed by linear and Lowess data normalization were
performed by using Feature Extraction software (Agilent Tech-
nologies). Quality control metrics were calculated by using this
software and the arrays, which reached the 12/12 points among
the 12 qualitative experimental aspects assessed (reproducibility
of spike-in RNAs, maximum acceptable background, quantifica-
tion of the outliers, reproducibility of the replicated spots on the
arrays, etc.) were included in the analysis. Statistical analyses of
microarray data were performed with the Genespring GX software
(Agilent Technologies).
miRNA EXPRESSION ANALYSIS
The miRNA were reverse-transcribed and amplified by PCR using
the multiplex RT TaqMan MicroRNA Low Density Array (LDA) kit
(Applied Biosystem, Foster City, CA, USA). An amount of 700 ng
total RNA was used for each sample. The global miRNA profiling
for human miRNA (756 miR probes) was then performed by using
the TaqMan LDA Human microRNA Panel (Applied Biosystem).
All the quality control tests were validated: blanks and repro-
ducibility [standard deviation of cycle threshold (CT)< 1] with
the two small nucleolar house-keeping RNAs RNU48 (SNORD48)
and RNU44 (SNORD44). The amount of RNA from each sample
was calibrated to RNU48 that had the smallest standard devia-
tion of all miRNA. This value gave a delta CT (∆CT) value for
each miR (miR CT value – RNU48 CT value). The average ∆CT
was calculated for responders and non-responders and the delta
∆CTs (∆∆CTs) corresponded to the difference in ∆CT between
the two categories. Fold changes (FC) were calculated as 2−∆∆CT
for up-regulated, as a decrease in one CT value was equivalent to
a twofold increase in the starting amount of cDNA, and by 2∆∆CT
for down-regulated miRNA.
INTERNAL VALIDATION OF THE GENES FOUND IN MICROARRAYS
ANALYSES BY RT-qPCR
The reverse transcriptase quantitative PCR (RT-qPCR) was done
by TaqMan. The qPCR reaction consisted to use the Mesa Green
qPCR Master-Mix Plus diluted 2×, 300 nM of forward and reverse
primers, and diluted template cDNA in a range of 5 and 10×, in
function of the RNA quantity assessed by the NanoDrop ND-1000
spectrophotometer. Cycling was performed at the following con-
ditions: 15 min at 42°C, 3 min at 95°C followed by 40 rounds of
15 s at 95°C, 20 s at 60°C, and 40 s at 72°C. The assay included two
no-template controls that consisted of the same samples without
the reverse transcription and a control of potential non-specific
amplifications by using melting curves.
STATISTICAL CONSIDERATIONS
The primary objective of the study was to identify a molecular
signature to predict response to chemotherapy in patients with
NSCLC. The secondary objectives were to identify prognostic
signatures for survival and progression-free survival. Statistical
considerations are detailed at www.elcwp.org. The lack of data
and the absence of guidelines in this particular setting led us to
make assumptions on the study power with different scenarios.
So, assuming the existence of a predictive signature, we calculated
the power to detect the effect of the signature on response, with
varying rates of patients with a predictive signature of response
(between 10 and 50%) for standard chemotherapy and for three
different values for objective response rate overall. We also tar-
geted a response rate among patients predicted to be responders
of 75% at least. The power, including a minimum of 15 patients
evaluable for objective response to perform the genetic analy-
sis in the derivation group, was more than 80% in almost all
circumstances with predicted response rates above 20% (power
0.90–1.00) except in the situation of low rates (<20%, power
0.47–0.80) of patients predicted to be responders, but in this
case the signature can be considered as not sensitive enough
and then without clinical usefulness. According to the protocol,
the signature should be confirmed in an independent validation
group.
Differences between responders and non-responders accord-
ing to clinical characteristics were assessed by t -tests or a Fisher’s
Exact tests. We applied t -tests for comparing mRNA expression
and Wilcoxon test for miRNA expression between responders and
non-responders, after adjusting for multiplicity testing using the
Benjamini–Hochberg (BH) method (12). False discovery rate was
set to 5%. The signature for response was derived using logis-
tic regression with stepwise variable selection. The associations
between overall survival and mRNA or miRNA expression levels
were estimated by using the Kaplan–Meier method and a log-
rank test. Cox proportional hazard regression models were applied
to estimate the hazard ratios. The signatures for overall survival
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were derived using Cox proportional hazards models with stepwise
variable selection.
RESULTS
From 1/04/2009 to 12/06/2013, 308 patients, with a high suspicion
of lung cancer based on lung lesion on chest CT scan,were prospec-
tively registered (Figure 1). Seven patients further denied their
initial consent, leaving 301 patients assessable for the study. In 25
cases, the diagnosis of lung cancer could not be confirmed. The two
main reasons were malignant tumor from another site (n= 13) or
a benign disease (n= 6). Despite the clinical suspicion, no patho-
logic confirmation could be obtained in six cases. A pathological
diagnosis of lung cancer was found in 276 patients, either on sam-
ples obtained at bronchoscopy or during a subsequent procedure.
Among them, there were 39 small cell lung cancers leaving 237
NSCLC for further analyses.
Among the 237 NSCLC, no tissue sample eligible for the
genomic analyses can be obtained in 114 cases. From the remain-
ing 123 patients, 16 did not receive any treatment (exclusive
palliative care and/or rapid alteration of the general status not
allowing any anticancer therapy) and 14 were treated with cura-
tive intent including a local treatment not allowing evaluation of
chemotherapy activity (eight surgery and six radiochemotherapy).
Among 93 patients benefiting from chemotherapy, 76 did
receive a combination of cisplatin (60 mg/m2 day 1) and vinorel-
bine (25 mg/m2 days 1 and 8). From these 76 patients (Figure 2),
eight were not assessable for response and at the time of analysis,
one patient was still under therapy and not yet assessed. Sixty-
seven patients were evaluable for response but only 55 samples
were adequate for performing microarrays (mRNA), the other 11
showing either insufficient quantity (n= 2), poor quality (n= 9),
or unassessable for technological consideration (n= 1). The first
34 patients were included in the derivation group and the further
21 ones in the validation one. Sixty patients could be included
in the miRNA analyses, the first 38 for the derivation group and
the further consecutive 22 for the validation one. In seven cases,
RNA was in insufficient quantity. The main characteristics of the
patients are reported in the Table 1. No statistically significant dif-
ferences were observed between the derivation and validation sets
concerning clinical characteristics, response rate, or survival times.
mRNA ANALYSES
Derivation group
Constructing a signature predicting response to cisplatin–
vinorelbine. Thirty-four patients were assessable for response
and mRNA analyses in the derivation group. Among those 34
patients, we observed 14 objective responses (41%) confirmed
by an independent panel of ELCWP investigators. Data were
imported in Genespring as Agilent two-color data, preprocessed
by Feature Extraction software with normalization and baseline
to median transformation of all samples. All quality indicators
appeared correct with and without baseline transformation.
We removed from the 41,093 probes the 14,523 that were not
expressed in any of the samples, leaving 26,570 probes for the
analyses. If we restricted to only the probes with detected inten-
sities in all of the samples of at least one experimental condition
(response/non-response), then out of the 41,093 probes, 26,567
would have been retained. If we had restricted only to the probes
with detected intensities in all of the samples for both response
and non-response, then out of the 41,093 probes, 24,609 probes
would have been retained, but potentially interesting biological
changes between response and non-response might be missed.
Therefore, we have decreased the stringency of the filter such that
even if the gene is only expressed (associated with detected or
308 registered patients
64 without final 
NSCLC diagnosis
237 NSCLC
7 denied informed 
consent
SCLC 39
Other malignancy 13
No pathological confirmation 6
Benign disease 6
No tissue for the study 114
No treatment 16
Surgery 8
RT-CT 6
Chemotherapy 93
Cisplatin-vinorelbine 
76
FIGURE 1 | Flow chart of registered patients. NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; RT-CT, radiochemotherapy.
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Cisplatin-vinorelbine 76
67 assessable for response
8 unassessable patients
1 treatment still ongoing
mRNA miRNA
7 inadequate quantity
Derivation: 38
Validation: 22
2 inadequate quantity
9 inadequate integrity
1 technical reason for RT-PCR
Derivation : 34
Validation : 21
FIGURE 2 | Flow chart of the patients treated with cisplatin–vinorelbine for transcriptomic analysis.
marginal intensity) in all of the samples in any experimental con-
dition (response/non-response), the probe will pass the filter. So,
only undetected probes were removed.
We applied t -tests (asymptotic p-value) for comparing mRNAs
expression according to response, after adjusting for multiplic-
ity testing [false discovery rate (FDR) according to BH method
<0.05]. We found 115 mRNAs differentially expressed between
responders and non-responders (Table 2), 50 mRNAs having a FC
>2 and 19 with a FC >3 (Table 3).
We restricted further analyses to the mRNAs with a fold change
of at least two. Among the 50 mRNAs differentially expressed, 34
were up-regulated and 16 down-regulated in non-responders in
comparison with responders. We calculated the area under the
ROC curve for each mRNA to predict response (genes detailed in
Table 4). After a stepwise variable selection on the 50 mRNAs, two
variables (FCN1 and RNF168) were retained. The area under the
ROC curve, when including both FCN1 and RNF168, was 0.97
[95% confidence interval (CI) 0.91–1]. It allowed constructing
a signature predicting response to cisplatin–vinorelbine summa-
rized as−2*FCN1+ 5*RNF168. At the best threshold of >2.3, the
signature had 93% (13/14) sensitivity, 100% (20/20) specificity,
100% (13/13) positive predictive value, and 95% (20/21) negative
predictive value (Table 5).
As a FC >3 is another limit accepted in the literature, we per-
formed the analysis with the same methodology, restricted to the
19 mRNAs with a FC above 3. Three were down-regulated and 16
up-regulated in non-responders in comparison with responders.
After a stepwise variable selection on the 19 mRNAs, two vari-
ables (KRT16 and SEMA3D) were retained. KRT16 had a FC of
14, SEMA3D a FC of 4 (Table 2). The area under the ROC curve,
when including both KRT16 and SEMA3D, was 0.95 (95% CI
0.89–1). The signature (KRT16+ 2*SEMA3D) allowed predicting
response with 100% (14/14) sensitivity, 100% negative predictive
value (14/14), 70% specificity (14/20), and 70% (14/20) positive
predictive value with a best cut-off of −2 (Table 5).
The mRNAs found in the two signatures were further validated
in the same patients by RT-qPCR (Table 6). The following for-
ward (Fw) and reverse (Rev) primers were used for the selected
genes FCN1 (Fw: TAGAGCTGGGGGACTCTTCA; Rev: CCAC-
CTTCACCTCTGGACAT), RNF168 (Fw: TTGGCAGAGGAG-
GAAGAAGA; Rev: TCAAGGGAGAAGCCGAGATA), KRT16 (Fw:
GTGAAGATCCGTGACTGGTA; Rev: GCAATGATCTTGTTC-
CTCAG), and SEMA3D (Fw: TGGAATTGTCTCTGAAGCAGC;
Rev: TGCGCAAGGTTTCCCATAAG). They were for the ref-
erence genes HPRT (Fw: GGTCAGGCAGTATAATCCAAAG;
Rev: AAGGGCATATCCTACAACAAAC) and β-actin (Fw: CGC-
CGCCAGCTCACCATG; Rev: CACGATGGAGGGGAAGACGG).
Using this methodology,we could confirm in that group of patients
that the four genes were differentially expressed with a high
statistical significance between responders and non-responders.
The p-value were respectively 0.006 (FCN1), 0.008 (RNF168),
0.002 (KRT16), and 0.005 (SEMA3D). When normalized with
the reference gene HPRT, all except RNF168 retained their sta-
tistical significance with respective p-value of <0.01 (FCN1-
HPRT), 0.68 (RNF168-HPRT), 0.002 (KRT16-HPRT), and 0.06
(SEMA3D-HPRT).
We measured the diagnostic performance of both signatures
by comparing their area under the ROC curve. No statistical
difference was noted (p= 0.58).
Constructingaprognostic signature for survival andprogression-
free survival. Using the same statistical methodology, we con-
structed a signature specifically predicting overall survival using
the mRNAs with a FC >3. The signature included two mRNAs
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Table 1 | Main characteristics of the patients included in the mRNA
analyses.
Derivation
group
(N =38)
Validation
group
(N =22)
P -value
Gender
Male 27 (71%) 17 (77%) 0.60
female 11 (29%) 5 (23%)
Age
Mean±STD 59±11 62±10 0.27
Median (min–max) 60 (33–78) 62 (45–76)
Karnofsky PS
50 – – 1 (5%)
60 2 (5%) 1 (5%)
70 9 (24%) 1 (5%)
80 6 (16%) 6 (30%)
90 17 (45%) 9 (45%)
100 4 (11%) 2 (10%)
Missing data 2
Median (min–max) 90 (60–100) 90 (50–100) 0.83
Metastases
No 8 (21%) 7 (32%) 0.36
Yes 30 (79%) 15 (68%)
Histology
Adenocarcinoma 20 (53%) 8 (36%) 0.44
Squamous 15 (39%) 12 (55%)
NSCLC NOS 3 (8%) 2 (9%)
Response to
chemotherapy
No response 21 (57%) 13 (59%) 0.86
Response 16 (43%) 9 (41%)
Unassessable 1
Median OS
(months) (95% CI)
25 (19–40) 29 (15–40) 0.63
OS, overall survival; PS, performance status; NOS, not otherwise specified.
(KRT16 and ULBP2) and was designed as−3*KRT16+ 2*ULBP2.
At the best cut-off of 1, it allowed distinguishing patients with
poor and good overall survival (HR 22.2, 95% CI 4.6–107.7; log-
rank and Wilcoxon test p < 0.001) (Figure 3, Table 7). Respective
median survival times were for the “good overall survival group”
of 40 months (95% CI 25–52 months) and for the “poor overall
survival group” of 15 months (95% CI 7–19 months). The same
signature was statistically significantly predicting progression-free
survival (HR 3.8, 95% CI 1.5–9.3; p < 0.001). Respective median
progression-free survival times were for the “good overall sur-
vival group” of 18.6 months (95% CI, 12.3–27.3 months) and
for the “poor overall survival group” of 8.1 months (95% CI,
5.8–15.5 months).
Validation group
Reverse transcriptase quantitative PCR for the five genes included
in the two predictive signatures and the one prognostic signature
(FCN1, RNF168, KRT16, SEMA3D, and ULBP2) were performed
on 22 samples from 22 patients treated with cisplatin–vinorelbine.
One sample was excluded as the CT values for the two refer-
ence genes (HPRT and β-actin) were above 32, leaving 21 patients
assessable for validating the signatures. Nine objective responses
were observed. Whatever correcting for actin or HPRT, no gene
was anymore differentially expressed with statistical significance
between responders and non-responders (Table 8). However, we
observed a statistically significant difference between the 12 non-
responders and the 9 responders in the expression of the two
reference genes actin (t -test p < 0.001, Wilcoxon p 0.046) and
HPRT (t -test p 0.005, Wilcoxon p 0.056).
As no gene could be validated, we repeated the same microarray
procedure for selecting variables in the 21 patients included in the
validation set and tested by RT-qPCR. From the 41,093 probes,
25,693 allowed detection of a signal in at least all of the patients
in one group (response/non-response). When applying t -tests
(asymptotic p-value) for comparing mRNAs expression according
to response, after adjusting for multiplicity testing (FDR< 0.05),
no gene could be retained. We further tested both predictive and
prognostic signature. None of them retained their statistical sig-
nificance in the validation group, with p-values of 0.20 (signature
for response) and 0.27 (signature for survival), respectively.
As an exploratory analysis, we also looked at genes differentially
expressed between responders and non-responders, in common
between the derivation and validation groups. For this purpose,
we performed asymptotic t -tests without FDR application. Three
thousand nine hundred ninety-four and 4597 genes were retained
respectively in the derivation and validation sets, of which 402 were
in common in both sets. Only 153 of them are regulated in the same
direction, but only 10 probes had a differential expression between
responders and non-responders at an FDR uncorrected p-value
<0.01 in both sets and only one with a FC>2 in both sets. They are
KCTD1, ALDH3B2, IQCB1, CHCHD6, RMND5A, NRP1 (tran-
script variant 3), RPS6KA5, C17orf69, NRP1 (transcript variant
1), and IQCB2P.
miRNA ANALYSES
Derivation group
Constructing signatures predicting response to cisplatin–
vinorelbine and prognostic for survival. The results concerning
the development of predictive and prognostic signatures based
on tumoral miRNAs in the derivation group have been previ-
ously published (9). Briefly, miRNAs analyses were performed
in 38 patients of whom one was not assessable for response.
Sixteen objective responses (43%) were observed. Of the 756 miR-
NAs, 396 had a CT> 32 in all patients and were excluded from
the analysis. Thirty-eight miRNAs were differentially expressed
between responders and non-responders with a p-value< 0.05. If
we applied the BH method for controlling the FDR for multiple
testing, none of them could be retained. However, without FDR
selection, a two miRNAs signature was designed: −4*hsa-miR-
149+ 3*hsa-miR-375 with a score above −6 predicting response
with an area under the ROC curve of 0.90 and 88% sensitivity,
81% specificity, 78% positive, and 89% negative predictive values.
To challenge the signature, we analyzed the prognostic value
of miRNAs for overall survival among 38 patients, 25 being
dead at the time of analysis. After stepwise selection, four miR-
NAs were included in a prognostic score. The signature was
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Table 2 | List of 115 genes differentially expressed between responders and non-responders in the derivation group.
Fold
change
Probe name Response
(mean
value)
No response
(mean
value)
Difference
in mean
values
Fold change
(response vs.
no response)
Absolute
fold
change
Regulation
(response vs.
no response)
FDR
corrected
p-value
Uncorrected
p-value
Gene
symbol
FC>4 A_23_P38537 2.4904087 −1.35274 3.8431487 14.351689 14.351689 Up 2.16E-02 8.13E-06 KRT16
FC>4 A_23_P23296 2.3682325 −0.70072174 3.0689542 8.391648 8.391648 Up 3.20E-02 2.91E-05 PKP1
FC>4 A_32_P168973 2.0731359 −0.94601595 3.0191517 8.106908 8.106908 Up 3.26E-02 7.61E-05 MGC102966
FC>4 A_24_P228149 2.0986717 −0.45802718 2.5566988 5.8835983 5.8835983 Up 3.26E-02 6.87E-05 KRT13
FC>4 A_23_P63736 1.6036273 −0.8539755 2.4576027 5.493032 5.493032 Up 1.39E-02 3.31E-06 LOC84856
FC>4 A_23_P93737 1.7272507 −0.36085242 2.088103 4.2518864 4.2518864 Up 4.04E-02 1.17E-04 DYNC1I1
FC>4 A_32_P29118 1.1011099 −0.9703983 2.0715082 4.2032585 4.2032585 Up 4.92E-02 2.11E-04 SEMA3D
FC>4 A_23_P405287 1.3622949 −0.7057522 2.068047 4.1931868 4.1931868 Up 3.20E-02 4.81E-05 SEMA3D
FC>3 A_23_P145485 1.3383486 −0.6611513 1.9994999 3.9986138 3.9986138 Up 3.20E-02 4.41E-05 ULBP2
FC>3 A_24_P149314 1.3553609 −0.5968727 1.9522336 3.8697317 3.8697317 Up 3.85E-02 1.10E-04 ULBP2
FC>3 A_23_P168259 1.3069798 −0.6392596 1.9462394 3.8536868 3.8536868 Up 3.26E-02 7.40E-05 ULBP2
FC>3 A_24_P55295 1.029862 −0.8678826 1.8977447 3.7263021 3.7263021 Up 3.26E-02 6.36E-05 GJA1
FC>3 A_24_P260134 1.5008985 −0.35766622 1.8585647 3.626467 3.626467 Up 3.03E-02 2.48E-05 NMNAT3
FC>3 A_23_P212665 1.3599136 −0.40204343 1.761957 3.391579 3.391579 Up 3.20E-02 3.70E-05 ABCC5
FC>3 A_24_P402588 0.9555351 −0.75297946 1.7085146 3.2682414 3.2682414 Up 4.77E-02 1.90E-04 BCL11A
FC>3 A_24_P15621 1.1812744 −0.41237277 1.5936472 3.0181139 3.0181139 Up 4.84E-02 2.00E-04 SLC6A10P
FC>2 A_24_P50890 1.0291404 −0.41876024 1.4479005 2.7281077 2.7281077 Up 3.74E-02 1.03E-04 PVRL1
FC>2 A_23_P120467 1.2124797 −0.22860909 1.4410888 2.7152572 2.7152572 Up 3.20E-02 4.77E-05 ZFP64
FC>2 A_23_P209904 0.95239705 −0.44006458 1.3924617 2.6252625 2.6252625 Up 3.26E-02 7.05E-05 GPC1
FC>2 A_23_P211401 0.8455327 −0.5219133 1.367446 2.580134 2.580134 Up 3.20E-02 3.70E-05 KREMEN1
FC>2 A_23_P76034 0.97714347 −0.36702603 1.3441695 2.53884 2.53884 Up 3.26E-02 6.86E-05 PVRL1
FC>2 A_23_P365785 0.65030813 −0.6916805 1.3419886 2.5350049 2.5350049 Up 3.52E-02 8.95E-05 GRHL1
FC>2 A_24_P351283 1.0064123 −0.33283657 1.3392489 2.5301955 2.5301955 Up 2.54E-02 1.34E-05 MREG
FC>2 A_32_P78943 1.0684785 −0.14730063 1.2157791 2.3226616 2.3226616 Up 4.73E-02 1.87E-04
FC>2 A_24_P371399 1.0383815 −0.17136136 1.2097428 2.312964 2.312964 Up 3.20E-02 3.80E-05 C3orf58
FC>2 A_23_P210763 0.8555546 −0.28793192 1.1434865 2.2091424 2.2091424 Up 3.26E-02 7.43E-05 JAG1
FC>2 A_23_P144134 0.92170376 −0.19656532 1.1182691 2.1708636 2.1708636 Up 4.31E-02 1.45E-04 C3orf58
FC>2 A_24_P567454 0.9409114 −0.1519253 1.0928367 2.1329303 2.1329303 Up 3.13E-03 2.66E-07 RNF168
FC>2 A_32_P26443 0.66768515 −0.4232059 1.0908911 2.1300557 2.1300557 Up 3.20E-02 3.53E-05 C3orf21
FC>2 A_23_P18196 0.67252 −0.3965082 1.0690281 2.0980196 2.0980196 Up 3.26E-02 6.66E-05 RFC4
FC>2 A_24_P46171 0.78893715 −0.26471114 1.0536482 2.0757723 2.0757723 Up 3.20E-02 4.65E-05 PIGX
FC>2 A_23_P354170 0.74245876 −0.30971533 1.0521741 2.0736525 2.0736525 Up 1.24E-02 2.33E-06 PIGX
FC>2 A_24_P123119 0.6953678 −0.35124567 1.0466135 2.0656753 2.0656753 Up 3.74E-02 1.02E-04 EHHADH
FC>2 A_24_P123190 0.6343807 −0.3929577 1.0273384 2.0382605 2.0382605 Up 4.73E-02 1.85E-04 PLD1
A_23_P108948 0.7275434 −0.25510627 0.9826497 1.9760914 1.9760914 Up 3.26E-02 6.88E-05 MREG
A_24_P23400 0.8408562 −0.13957612 0.98043233 1.9730566 1.9730566 Up 3.26E-02 7.49E-05 SLC6A8
A_24_P111737 0.8168281 −0.14033504 0.9571631 1.9414884 1.9414884 Up 3.26E-02 6.39E-05 ATP11B
A_32_P195291 0.7964409 −0.15760839 0.9540493 1.9373026 1.9373026 Up 3.20E-02 3.34E-05 RNF168
A_23_P69121 0.82585055 −0.10896964 0.9348202 1.9116523 1.9116523 Up 4.73E-02 1.83E-04 SIAH2
A_23_P400794 0.6963362 −0.23828867 0.9346249 1.9113936 1.9113936 Up 3.26E-02 6.38E-05 FBXO45
A_24_P406245 0.71501625 −0.21661237 0.9316286 1.907428 1.907428 Up 3.20E-02 4.06E-05 PMS2L2
A_24_P340428 0.67214394 −0.25692314 0.9290671 1.9040444 1.9040444 Up 1.39E-02 3.66E-06 ATP11B
A_23_P16944 0.77089965 −0.14973187 0.9206315 1.8929437 1.8929437 Up 4.60E-02 1.71E-04 SDC1
A_23_P31135 0.5873326 −0.32817858 0.9155112 1.8862373 1.8862373 Up 4.07E-02 1.26E-04 ACAT2
A_23_P69249 0.67190737 −0.23103127 0.9029386 1.8698708 1.8698708 Up 2.59E-02 1.54E-05 ACTL6A
A_23_P69437 0.58162504 −0.31927863 0.9009037 1.8672353 1.8672353 Up 4.73E-02 1.85E-04 YEATS2
A_32_P97192 0.6328155 −0.2644442 0.8972597 1.8625249 1.8625249 Up 3.26E-02 5.55E-05 PMS2L2
A_23_P5936 0.4895308 −0.39759988 0.8871307 1.8494941 1.8494941 Up 4.31E-02 1.41E-04 C20orf117
A_23_P345710 0.7339968 −0.15165368 0.8856505 1.8475975 1.8475975 Up 3.13E-03 1.65E-07 C3orf21
A_23_P134295 0.5280118 −0.35337663 0.8813884 1.8421474 1.8421474 Up 3.26E-02 7.37E-05 NUDT1
A_24_P291588 0.6312908 −0.24706182 0.87835264 1.8382751 1.8382751 Up 2.41E-02 9.97E-06 DVL3
A_23_P358221 0.68547153 −0.1714746 0.8569461 1.8112003 1.8112003 Up 1.24E-02 2.09E-06 UBXN7
A_23_P119084 0.54716736 −0.3036831 0.85085046 1.8035638 1.8035638 Up 4.81E-02 1.97E-04 ZNF551
A_23_P416142 0.6109084 −0.22270343 0.83361185 1.7821414 1.7821414 Up 2.54E-02 1.29E-05 DLG1
A_23_P212522 0.6316152 −0.19792378 0.829539 1.7771174 1.7771174 Up 2.79E-02 2.00E-05 ATP11B
A_23_P212034 0.63048804 −0.19111416 0.8216022 1.7673677 1.7673677 Up 4.33E-02 1.54E-04 DLG1
A_24_P944444 0.51009727 −0.29740423 0.8075015 1.7501779 1.7501779 Up 3.20E-02 3.09E-05 MAPKBP1
(Continued)
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Table 2 | Continued
Fold
change
Probe name Response
(mean
value)
No response
(mean
value)
Difference
in mean
values
Fold change
(response vs.
no response)
Absolute
fold
change
Regulation
(response vs.
no response)
FDR
corrected
p-value
Uncorrected
p-value
Gene
symbol
A_23_P395075 0.58912766 −0.20520839 0.7943361 1.734279 1.734279 Up 4.81E-02 1.94E-04 KDM3A
A_24_P166012 0.55840063 −0.23510353 0.7935042 1.7332793 1.7332793 Up 3.03E-02 2.51E-05 DCUN1D1
A_23_P155316 0.48434967 −0.30781966 0.79216933 1.7316763 1.7316763 Up 4.31E-02 1.43E-04 NCBP2
A_32_P16258 0.6029671 −0.17862633 0.78159344 1.7190285 1.7190285 Up 4.92E-02 2.13E-04 EXOC6B
A_23_P144151 0.65791667 −0.10735836 0.765275 1.6996939 1.6996939 Up 3.52E-02 9.10E-05
A_23_P18102 0.40448546 −0.3493367 0.7538222 1.6862544 1.6862544 Up 3.20E-02 5.00E-05 SENP5
A_23_P218884 0.48295045 −0.27010906 0.7530595 1.6853632 1.6853632 Up 3.20E-02 4.32E-05 DVL3
A_32_P222515 0.5415697 −0.18197708 0.7235468 1.6512365 1.6512365 Up 3.26E-02 6.53E-05 UBXN7
A_23_P258037 0.5379724 −0.17757766 0.71555007 1.6421092 1.6421092 Up 3.20E-02 5.06E-05 KDM3A
A_24_P105761 0.52657336 −0.18410102 0.7106744 1.636569 1.636569 Up 4.73E-02 1.80E-04 KDM3A
A_23_P110062 0.51333207 −0.19231682 0.7056489 1.6308781 1.6308781 Up 4.07E-02 1.29E-04 EIF2B5
A_24_P210675 0.45133168 −0.24289604 0.6942277 1.618018 1.618018 Up 4.92E-02 2.13E-04 NDE1
A_23_P29504 0.55088145 −0.11576251 0.666644 1.5873761 1.5873761 Up 3.26E-02 7.21E-05 SENP5
A_24_P76666 0.35812706 −0.29609442 0.6542215 1.5737665 1.5737665 Up 3.20E-02 4.38E-05 CSNK2A1
A_23_P431587 0.36161706 −0.26871416 0.6303312 1.5479203 1.5479203 Up 4.07E-02 1.24E-04 VPS8
A_32_P32653 0.41394213 −0.21419649 0.6281386 1.5455695 1.5455695 Up 3.60E-02 9.62E-05 SENP5
A_23_P101342 0.488292 −0.1337074 0.6219994 1.5390066 1.5390066 Up 2.72E-02 1.84E-05 ATG4D
A_23_P44956 0.43706688 −0.16102271 0.5980896 1.5137107 1.5137107 Up 3.80E-02 1.07E-04 RPL35A
A_32_P32179 0.4339779 −0.15347187 0.5874498 1.5025883 1.5025883 Up 2.54E-02 1.29E-05
A_23_P427622 0.5676906 0.013194157 0.55449647 1.468656 1.468656 Up 4.81E-02 1.96E-04 UNQ1887
A_23_P110076 0.33755684 −0.20134711 0.53890395 1.4528683 1.4528683 Up 4.34E-02 1.57E-04 WDR53
A_32_P132477 0.38293335 −0.15272838 0.5356617 1.4496069 1.4496069 Up 4.07E-02 1.20E-04
A_23_P346206 0.36038876 −0.16280492 0.52319366 1.4371331 1.4371331 Up 3.52E-02 8.74E-05 RAE1
A_23_P317854 0.29310012 −0.1636454 0.4567455 1.3724424 1.3724424 Up 3.74E-02 1.04E-04 MED26
A_24_P225907 −0.3019109 0.15964396 −0.46155488 −1.3770251 1.3770251 Down 4.07E-02 1.21E-04 DPH3
A_24_P205230 −0.35831454 0.16462934 −0.52294385 −1.4368843 1.4368843 Down 4.07E-02 1.26E-04 RNASEK
A_24_P166094 −0.4055858 0.13177143 −0.5373572 −1.4513115 1.4513115 Down 4.44E-02 1.62E-04 ARFIP1
A_23_P205913 −0.42380837 0.11410071 −0.5379091 −1.4518667 1.4518667 Down 4.58E-02 1.69E-04 SLC24A1
A_23_P152066 −0.46616426 0.09878205 −0.5649463 −1.4793324 1.4793324 Down 3.13E-03 3.53E-07 UBR1
A_23_P58002 −0.41184562 0.1589065 −0.57075214 −1.4852977 1.4852977 Down 4.31E-02 1.46E-04 TCTA
A_24_P71153 −0.37698016 0.19527814 −0.5722583 −1.4868492 1.4868492 Down 3.45E-02 8.32E-05 PAFAH2
A_23_P77562 −0.37067208 0.2450805 −0.6157526 −1.5323571 1.5323571 Down 3.26E-02 5.87E-05 TMEM219
A_23_P412392 −0.29659137 0.33060193 −0.62719333 −1.5445572 1.5445572 Down 3.20E-02 4.44E-05 SEC22B
A_24_P551302 −0.38215917 0.2763248 −0.658484 −1.5784231 1.5784231 Down 3.26E-02 6.83E-05
A_23_P40866 −0.4178533 0.25824612 −0.6760994 −1.597814 1.597814 Down 3.35E-02 7.95E-05 ZBTB20
A_23_P72503 −0.4167065 0.27814037 −0.69484687 −1.6187127 1.6187127 Down 3.03E-02 2.37E-05 KLHL2
A_24_P823708 −0.44348216 0.27844223 −0.7219244 −1.6493807 1.6493807 Down 3.20E-02 5.03E-05 LOC728855
A_23_P503182 −0.49898216 0.23469424 −0.73367643 −1.6628712 1.6628712 Down 3.20E-02 4.01E-05 ABR
A_32_P28476 −0.5130292 0.2420673 −0.75509655 −1.6877445 1.6877445 Down 3.09E-02 2.68E-05
A_32_P193091 −0.55347806 0.28480965 −0.8382877 −1.7879268 1.7879268 Down 4.33E-02 1.51E-04
A_23_P12463 −0.6446937 0.28819558 −0.9328892 −1.9090954 1.9090954 Down 4.31E-02 1.40E-04 QSOX1
A_23_P108751 −0.538324 0.45318156 −0.99150556 −1.9882588 1.9882588 Down 3.58E-02 9.43E-05 FHL2
FC>2 A_23_P150325 −0.6769149 0.36179325 −1.0387081 −2.054387 2.054387 Down 4.07E-02 1.27E-04 TMEM133
FC>2 A_23_P157879 −0.8153628 0.28951484 −1.1048777 −2.1508064 2.1508064 Down 4.33E-02 1.52E-04 FCN1
FC>2 A_24_P152649 −0.6403896 0.48672542 −1.127115 −2.1842153 2.1842153 Down 4.31E-02 1.41E-04 LOC644189
FC>2 A_23_P149562 −0.627059 0.5123564 −1.1394154 −2.2029173 2.2029173 Down 4.85E-02 2.03E-04 ARHGAP29
FC>2 A_24_P269006 −0.7269329 0.4633929 −1.1903257 −2.2820425 2.2820425 Down 4.33E-02 1.55E-04 ALDH7A1
FC>2 A_32_P486620 −0.9032537 0.303291 −1.2065446 −2.3078423 2.3078423 Down 4.66E-02 1.75E-04 IGSF22
FC>2 A_23_P94819 −0.8477721 0.36849847 −1.2162706 −2.3234532 2.3234532 Down 1.97E-02 5.94E-06 RPH3AL
FC>2 A_23_P201386 −0.72164166 0.49630338 −1.2179451 −2.3261516 2.3261516 Down 2.59E-02 1.65E-05 DDAH1
FC>2 A_24_P333571 −0.9850959 0.32136387 −1.3064598 −2.4733386 2.4733386 Down 3.52E-02 8.98E-05
FC>2 A_23_P116614 −1.1228174 0.27101618 −1.3938336 −2.6277602 2.6277602 Down 4.33E-02 1.54E-04 ME3
FC>2 A_23_P105227 −1.2048123 0.2538056 −1.4586179 −2.7484493 2.7484493 Down 3.26E-02 6.51E-05 ME3
FC>2 A_23_P148753 −1.0244241 0.4529644 −1.4773885 −2.7844424 2.7844424 Down 4.92E-02 2.12E-04 PLEKHA6
FC>2 A_23_P15272 −1.0517842 0.45105672 −1.5028409 −2.8340023 2.8340023 Down 3.52E-02 9.15E-05 ABCC6
FC>3 A_23_P431268 −1.0362521 0.62329584 −1.659548 −3.1591754 3.1591754 Down 2.16E-02 7.96E-06 PLEKHA6
FC>3 A_23_P10182 −1.0682763 0.7183502 −1.7866265 −3.450072 3.450072 Down 2.59E-02 1.60E-05 ACOX2
FC>4 A_23_P394246 −1.4391525 0.9436475 −2.3828 −5.2154803 5.2154803 Down 3.26E-02 6.28E-05 GPR81
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Table 3 | Number of genes differentially expressed in responders and
non-responders in the derivation group.
Without FDR correction With FDR<0.05
All fold change 26570 115
Fold change>1.1 15789 115
Fold change>1.5 2423 103
Fold change>2.0 516 50
Fold change>3.0 115 19
FDR, false discovery rate (according to the Benjamini–Hochberg method).
as follows: 3*hsa-miR-200c− 9*hsa-miR-29c− 2*hsa-miR-424−
2*hsa-miR-124. With a cut-off of−52, the signature distinguished
patients with good (n= 18) and poor (n= 20) prognosis with
respective median survival of 47.3 months (95% CI 29.8–52.4)
and 15.5 months (95% CI 9.1–22.8) (p < 0.001; hazard ratio 21.1,
95% CI 4.7–94.9). The same signature discriminated patients
with good progression-free survival (median 19.8 months; 95% CI
15.3–33.8) from the others (median 9.1 months; 95% CI 6.3–15.5)
(p < 0.001; hazard ratio 3.8, 95% CI 1.7–8.7).
Validation group
miRNAs analyses were performed on 22 patients included in the
validation set (Table 2). The difference between responders and
non-responders, in mean expression of the two miRNAs from
the predictive signature, was not statistically significant (miR-149,
p= 0.07 and miR-375, p= 0.11) (Table 9). Sensitivity, specificity,
positive, and negative predictive values of the signature were 33%
(3/9), 77% (10/13), 50% (3/6), and 63% (10/16), respectively.
Among the four miRNAs included in the prognostic signature,
only miR424 retained a borderline statistical significance for sur-
vival (HR 0.66, 95% CI 0.44–1.00, p= 0.05). The respective HR
value for the three other miRNAs were for miR200c 0.95 (95% CI
0.53–1.70, p= 0.85), for miR29c 1.00 (95% CI 0.43–2.34, p= 0.99)
and for miR124a 0.86 (95% CI 0.48–1.52, p= 0.59). The 4-miR
signature did not anymore distinguish patients with poor and good
prognosis.
We further looked at expression levels of the six selected
miRNAs involved in the predictive and prognostic signatures.
Statistically significant differences in the respective ∆CT values
were observed when comparing derivation and validation sets
(Table 10).
DISCUSSION
Herein, we report mature data of a prospective translational
academic study performed in advanced and metastatic NSCLC,
homogeneously treated with cisplatin–vinorelbine. In an attempt
of searching for biological markers predicting chemosensitivity
and prognostic for survival, we were able, in a derivation group,
to build predictive and prognostic biological signatures based on
mRNA and miRNA analyses by high throughput techniques. These
signatures could not be confirmed in an independent validation
group of patients treated in the same way. This study is underlying
the difficulties in obtaining, in routine practice, adequate biologi-
cal samples for translational research as well as the limitations for
using those signatures derived from high throughput techniques.
Only 10–15% of newly diagnosed NSCLC patients will ulti-
mately be cured (1). For the others, chemotherapy will be given
at least once during the course of the disease. Cisplatin-based
regimens are the cornerstone of 1st line chemotherapy for stage
IV NSCLC as well as the most common combination for adju-
vant therapy after surgery in completely resected stages II–III
disease and for combined chemoradiotherapy. However, at least
in patients treated with palliative intent, response rates are lim-
ited to 20–40% while substantial acute and chronic toxicities are
encountered. A better selection of patients able to benefit, or not,
from chemotherapy could theoretically help in selecting the most
effective drug combinations for a particular patient; this is the pur-
pose of customized chemotherapy. Data from randomized trials
and series are suggesting that patients with poor performance sta-
tus are less likely to benefit from chemotherapy than those with
a good one (13). Histology is also of importance with adenocar-
cinomas being more susceptible to pemetrexed than squamous
cell carcinomas (14). Nevertheless, there are no reliable individual
predictors of chemotherapy effectiveness.
During the last decades, a better understanding of the tumors’
biology allowed in some situations to propose very active treat-
ments when cancer is expressing a specific target. The best exam-
ples are oral tyrosine kinase inhibitors for EGFR activating muta-
tions (5) and ALK translocation (6), with response rates around
60%, whatever the line of treatment. Other targeted therapies
are currently under consideration but only a limited number of
patients will have access to these very effective drugs. For cytotoxic
chemotherapy, therapeutic strategies based on a genotypic analy-
sis have been tested in randomized trials and failed to improve the
common “same chemotherapy for all” approach (7, 8). Nonethe-
less, in these two trials, the number of considered genes was limited
to ERCC1 or both ERCC1 and RRM1 that seem unlikely repre-
senting an extensive view of the biological tumor heterogeneous
behavior. The problems in assessing multiple biological markers
are related to the sample volume, generally limited to small biop-
sies in advanced and metastatic diseases, and the time necessary
for performing multiple single analyses. This is an advantage for
high throughput techniques like microarrays allowing yet on small
samples to perform thousands of analyses at the same time. For this
reason, we designed this prospective study searching for biological
signatures both at the mRNA and miRNA levels.
Biological signatures have previously been published. Based
on mRNA analyses, they all are dealing with survival, eventu-
ally disease-free survival, mostly in surgical stages but none was
designed for searching a predictive marker of chemosensitivity.
Also surgical cases are mainly representing the population used
for miRNA analyses in which two signatures were tested for
chemosensitivity (15, 16).
To date, more than 40 different prognostic signatures for sur-
vival, based on mRNA analyses, have been published. The signa-
ture that we identified in the derivation group was never published
before. This is reflecting the large heterogeneity in the literature. In
a review, only 5 genes were overlapping in a total of 327 included
in seven signatures, and yet the 5 were not in common into all of
them (17). Among published signatures, in most of them, there
has never been any attempt to validate them in independent sets at
the difference of our study. But when authors tried to do so, they
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Table 4 | Area under ROC curve for the 50 genes differentially expressed between responders and non-responders with a fold change>2.
ProbeName GeneSymbol Area under
ROC curve
Description
A_23_P157879 FCN1 0.86 Homo sapiens ficolin (collagen/fibrinogen domain containing) 1 (FCN1), mRNA [NM_002003]
A_23_P144134 C3orf58 0.78 Homo sapiens chromosome 3 open reading frame 58 (C3orf58), transcript variant 1, mRNA
[NM_173552]
A_23_P394246 GPR81 0.87 Probable G-protein coupled receptor 81 (G-protein coupled receptor 104)
[Source:UniProtKB/Swiss-Prot;Acc:Q9BXC0] [ENST00000432564]
A_23_P431268 PLEKHA6 0.90 Homo sapiens pleckstrin homology domain containing, family A member 6 (PLEKHA6), mRNA
[NM_014935]
A_24_P269006 ALDH7A1 0.86 Homo sapiens aldehyde dehydrogenase 7 family, member A1 (ALDH7A1), mRNA [NM_001182]
A_23_P145485 ULBP2 0.89 Homo sapiens UL16 binding protein 2 (ULBP2), mRNA [NM_025217]
A_24_P228149 KRT13 0.85 Homo sapiens keratin 13 (KRT13), transcript variant 2, mRNA [NM_002274]
A_23_P23296 PKP1 0.88 Homo sapiens plakophilin 1 (ectodermal dysplasia/skin fragility syndrome) (PKP1), transcript variant
1b, mRNA [NM_000299]
A_32_P78943 0.78 CD025760 Human CD34( ESTs from primary hematopoietic stem-progenitor cells Homo sapiens
cDNA 3′, mRNA sequence [GD161310]
A_23_P105227 ME3 0.85 Homo sapiens malic enzyme 3, NADP(+)-dependent, mitochondrial (ME3), nuclear gene encoding
mitochondrial protein, transcript variant 2, mRNA [NM_001014811]
A_23_P10182 ACOX2 0.90 Homo sapiens acyl-Coenzyme A oxidase 2, branched chain (ACOX2), mRNA [NM_003500]
A_24_P402588 BCL11A 0.86 Homo sapiens B-cell CLL/lymphoma 11A (zinc finger protein) (BCL11A), transcript variant 2, mRNA
[NM_018014]
A_23_P94819 RPH3AL 0.91 Homo sapiens rabphilin 3A-like (without C2 domains) (RPH3AL), mRNA [NM_006987]
A_23_P211401 KREMEN1 0.85 Homo sapiens kringle containing transmembrane protein 1 (KREMEN1), transcript variant 3, mRNA
[NM_001039570]
A_24_P333571 0.87 Rho GTPase-activating protein 29 (Rho-type GTPase-activating protein 29)(PTPL1-associated
RhoGAP protein 1) [Source:UniProtKB/Swiss-Prot;Acc:Q52LW3] [ENST00000370217]
A_23_P63736 LOC84856 0.91 Homo sapiens hypothetical LOC84856 (LOC84856), non-coding RNA [NR_026827]
A_23_P150325 TMEM133 0.87 Homo sapiens transmembrane protein 133 (TMEM133), mRNA [NM_032021]
A_23_P209904 GPC1 0.85 Homo sapiens glypican 1 (GPC1), mRNA [NM_002081]
A_24_P567454 RNF168 0.94 E3 ubiquitin-protein ligase RNF168 (EC 6.3.2.-)(RING finger protein 168)
[Source:UniProtKB/Swiss-Prot;Acc:Q8IYW5] [ENST00000318037]
A_23_P38537 KRT16 0.90 Homo sapiens keratin 16 (KRT16), mRNA [NM_005557]
A_23_P365785 GRHL1 0.86 Homo sapiens grainyhead-like 1 (Drosophila) (GRHL1), mRNA [NM_198182]
A_24_P260134 NMNAT3 0.85 Homo sapiens nicotinamide nucleotide adenylyltransferase 3 (NMNAT3), mRNA [NM_178177]
A_23_P15272 ABCC6 0.87 Homo sapiens ATP-binding cassette, sub-family C (CFTR/MRP), member 6 (ABCC6), transcript
variant 2, mRNA [NM_001079528]
A_24_P123190 PLD1 0.87 Homo sapiens phospholipase D1, phosphatidylcholine-specific (PLD1), transcript variant 1, mRNA
[NM_002662]
A_32_P168973 MGC102966 0.86 Homo sapiens keratin 16 pseudogene (MGC102966), non-coding RNA [NR_029393]
A_23_P201386 DDAH1 0.90 Homo sapiens dimethylarginine dimethylaminohydrolase 1 (DDAH1), transcript variant 1, mRNA
[NM_012137]
(Continued)
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Table 4 | Continued
ProbeName GeneSymbol Area under
ROC curve
Description
A_32_P486620 IGSF22 0.84 Homo sapiens immunoglobulin superfamily, member 22 (IGSF22), mRNA [NM_173588]
A_24_P55295 GJA1 0.89 Homo sapiens gap junction protein, alpha 1, 43kDa (GJA1), mRNA [NM_000165]
A_32_P29118 SEMA3D 0.85 Homo sapiens sema domain, immunoglobulin domain (Ig), short basic domain, secreted,
(semaphorin) 3D (SEMA3D), mRNA [NM_152754]
A_24_P152649 LOC644189 0.87 PREDICTED: Homo sapiens similar to peroxisomal long-chain acyl-coA thioesterase (LOC644189),
miscRNA [XR_016949]
A_23_P168259 ULBP2 0.87 Homo sapiens UL16 binding protein 2 (ULBP2), mRNA [NM_025217]
A_24_P149314 ULBP2 0.86 Homo sapiens UL16 binding protein 2 (ULBP2), mRNA [NM_025217]
A_23_P120467 ZFP64 0.87 Homo sapiens zinc finger protein 64 homolog (mouse) (ZFP64), transcript variant 4, mRNA
[NM_199427]
A_24_P123119 EHHADH 0.89 Homo sapiens enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase
(EHHADH), transcript variant 1, mRNA [NM_001966]
A_24_P351283 MREG 0.90 Homo sapiens melanoregulin (MREG), mRNA [NM_018000]
A_24_P15621 SLC6A10P 0.82 Homo sapiens solute carrier family 6 (neurotransmitter transporter, creatine), member 10
(pseudogene) (SLC6A10P) on chromosome 16 [NR_003083]
A_24_P50890 PVRL1 0.83 Homo sapiens poliovirus receptor-related 1 (herpesvirus entry mediator C) (PVRL1), transcript
variant 1, mRNA [NM_002855]
A_24_P371399 C3orf58 0.81 Homo sapiens chromosome 3 open reading frame 58 (C3orf58), transcript variant 1, mRNA
[NM_173552]
A_23_P148753 PLEKHA6 0.83 Homo sapiens pleckstrin homology domain containing, family A member 6 (PLEKHA6), mRNA
[NM_014935]
A_32_P26443 C3orf21 0.86 Uncharacterized protein C3orf21 [Source:UniProtKB/Swiss-Prot;Acc:Q8NBI6] [ENST00000310380]
A_23_P405287 SEMA3D 0.87 Homo sapiens sema domain, immunoglobulin domain (Ig), short basic domain, secreted,
(semaphorin) 3D (SEMA3D), mRNA [NM_152754]
A_23_P149562 ARHGAP29 0.84 Homo sapiens Rho GTPase-activating protein 29 (ARHGAP29), mRNA [NM_004815]
A_23_P210763 JAG1 0.85 Homo sapiens jagged 1 (Alagille syndrome) (JAG1), mRNA [NM_000214]
A_23_P116614 ME3 0.84 Homo sapiens malic enzyme 3, NADP(+)-dependent, mitochondrial (ME3), nuclear gene encoding
mitochondrial protein, transcript variant 2, mRNA [NM_001014811]
A_23_P93737 DYNC1I1 0.83 Homo sapiens dynein, cytoplasmic 1, intermediate chain 1 (DYNC1I1), transcript variant 1, mRNA
[NM_004411]
A_23_P18196 RFC4 0.86 Homo sapiens replication factor C (activator 1) 4, 37kDa (RFC4), transcript variant 1, mRNA
[NM_002916]
A_23_P76034 PVRL1 0.88 Homo sapiens poliovirus receptor-related 1 (herpesvirus entry mediator C) (PVRL1), transcript
variant 3, mRNA [NM_203286]
A_23_P354170 PIGX 0.93 Homo sapiens phosphatidylinositol glycan anchor biosynthesis, class X (PIGX), transcript variant 2,
mRNA [NM_017861]
A_23_P212665 ABCC5 0.87 Homo sapiens ATP-binding cassette, sub-family C (CFTR/MRP), member 5 (ABCC5), transcript
variant 1, mRNA [NM_005688]
A_24_P46171 PIGX 0.87 Homo sapiens phosphatidylinositol glycan anchor biosynthesis, class X (PIGX), transcript variant 2,
mRNA [NM_017861]
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cannot systematically succeed to validate their prognostic signa-
tures (3). Potential explanations are related to heterogeneity in the
patients’ and treatment’s characteristics that are frequently poorly
or partially reported, to differences in the component of squa-
mous cell and adenocarcinomas, to the statistical tests used and to
the limited number of patients included in the trials that proba-
bly needs to be extensively increased for this type of translational
research (18). A last component associated with a lack of repro-
ducibility of those signatures is the heterogeneity in the platforms
whatever considering the type and the number of genes tested. In a
comparison of two common platforms, Affymetrix and Illumina,
authors showed that the number of selected genes and their nature
were not comparable with the two methods while performed on
the same samples (19).
Table 5 | Results of the stepwise regression and construction of
signature predicting response in patients treated with
cisplatin–vinorelbine based on mRNA analyses.
Genes with fold change>2 (n=50)
Estimate Standard error p
FCN1 −2.2393 1.0798 0.0381
RNF168 5.5365 2.4143 0.0218
Signature:
−2*FCN1+5*RNF168>2.3→ response
−2*FCN1+5*RNF168<2.3→no response
Genes with fold change>3 (n=19)
Estimate Standard error p
KRT16 0.7616 0.3250 0.0191
SEMA3D 1.3641 0.6383 0.0326
Signature:
KRT16+2*SEMA3D>−2→ response
KRT16+2*SEMA3D<−2→no response
The same observations are valid for miRNA signatures. The
main sources of heterogeneity are as follow: type of sam-
ples, mainly providing from surgery in patients not receiving
chemotherapy but in a few cases serum has been used; the number
of miRNA involved in the analyses, from a few ones to up to 880;
the different techniques, single RT-PCR for very limited number of
miRNA to various platforms for high throughput techniques that
also are not comparable. Among more than 25 studies assessing
the prognostic role of miRNA in NSCLC, the number of stud-
ies validated in an independent group of patients and taking into
account other prognostic factors in a multivariate analysis was
yet more limited (20–23). We found two publications analyzing
the predictive role of miRNA for response to chemotherapy. In
the first one, a secondary analysis from the adjuvant IALT trial
including 639 completely resected NSCLC (16), 7 miRNA were
considered for the analysis and the authors did not find any inter-
action with chemosensitivity. The second was done in a limited
group of 34 SCLC patients. A three miRNA signature was associ-
ated with objective response to chemotherapy (15). We discussed
the discrepancies between our study and the others in a previous
publication (9).
The present study is confirming these evidences from the litera-
ture. We were able to derive, from a small but homogeneous group
of patients, a single biological signature based on mRNA expres-
sion predictive of response to the cisplatin–vinorelbine regimen.
We internally validated the results obtained with the microarray
experiment by RT-qPCR, confirming the tumoral expression asso-
ciated with the selected mRNAs and their distinction between
responders and non-responders. This approach would have given
us the possibility to develop a rapid, cheaper test accessible to
most pathological laboratories at the difference of expensive and
difficult microarrays. However, the final data from the study after
attempting a validation in an independent group of patients with
the same high throughput techniques was a failure despite the
robust methodology of our prospective study. A major point to be
primarily considered is that statistics cannot have enough power
and reliability for approaching very complex biological analyses
involving thousands of genes/proteins. This problem has yet been
Table 6 | Internal validation of the four genes found in the two predictive signatures for response by RT-qPCR in the derivation set.
Variable Non-responders Responders P -value
N Mean ∆CT SD N Mean ∆CT SD
HPRT 17 27.1154287 1.0258238 14 26.1534160 0.9717660 0.027
FCN1 17 28.8819719 1.1437691 14 30.2759826 1.2235700 0.006
RNF168 17 26.9853971 0.9217302 14 25.8188423 1.1153445 0.008
KRT16 16 32.1516412 2.8771146 14 27.3871707 3.1949645 0.002
Sema3d 17 32.8827111 1.5138481 14 30.5694798 1.9132922 0.005
HPRTAS REFERENCE GENE
FCN1 17 1.7665432 1.3993750 14 4.1225666 1.4610938 <0.001
RNF168 17 −0.1300316 0.6584257 14 −0.3345736 0.7560190 0.68
KRT16 16 5.0245187 2.6242224 14 1.2337547 2.6897044 0.002
Sema3D 17 5.7672824 1.9953494 14 4.4160639 1.4020225 0.06
The tumoral expression of the selected mRNA included in the predictive signatures for response to cisplatin–vinorelbine was tested by RT-qPCR, and normalized with
the HPRT reference gene.
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FIGURE 3 | Overall survival curves according to the mRNA prognostic signature in the derivation group. MST, median survival time. Patients from the
derivation group could be dichotomized according to the mRNA prognostic signature (−3*KRT16+2*ULBP2). A value >1 is predicting a poor overall survival
while a value <1 is associated with a good overall survival.
Table 7 | Results of the stepwise Cox’s proportional hazards model
regression and construction of signature predicting survival in
patients treated with cisplatin–vinorelbine, based on mRNA analyses
in the derivation set.
Genes with fold change>3 (n=19)
Estimate Standard error p
KRT16 −0.55394 0.16090 0.0006
ULBP2 0.39724 0.18114 0.0283
Signature:
−3*KRT16+2*ULBP2>1→poor overall survival
−3*KRT16+2*ULBP2<1→good overall survival
evoked in the literature when the same group using different statis-
tics on the same samples found two distinct biological prognostic
signatures (24, 25).
Our data have main strengths of which the first is the prospec-
tive nature of the present study while the majority of the pub-
lished literature is dealing with retrospective studies using archival
tissues. All consecutive patients presenting with suspected lung
cancer were proposed to participate. This is limiting the risk of
recruitment bias. As this is a prospective study, we avoided the
risk of lack of data as regularly reported in retrospective series.
Further, our design has foreseen, from the outset, a validation of
our data in a distinct group of patients managed and treated in
the same way, allowing obtaining a very homogeneous group. The
validation group was treated in the same way as the derivation one
and presented with similar clinical characteristics able to influence
response rate and/or survival as gender, age, performance status,
or stage. This was reflected in the similar response rates and sur-
vival times with no statistically significant differences (respective
p-values of 0.86 and 0.63). The only non-statistically significant
difference was linked to histology with a predominance of squa-
mous cell carcinomas in the first group and adenocarcinomas in
the second. It was previously pointed out that signatures derived
in one histological type may not be applied in another, at least
for survival (26, 27). Also, this is not as common to find this
type of validation in the previous reported publications. Another
strength of our study is underlined by the fact that we repeated the
microarray experiment with the same methodology, after the fail-
ure of validation using RT-qPCR. Those microarrays as well as the
RT-qPCR were commercial tests that can easily be reproducible
at the difference of “home-made” techniques. Overall, we could
conclude that biological signatures have to be considered for pre-
dictive or prognostic purpose only if they are externally validated
in a group of patients presenting with the same clinical character-
istics, managed and treated in the same ways as in the derivation
group.
There are some limitations to our study. The first is the sta-
tistical design as there were no data or guidelines allowing us to
calculate the adequate number of patients to be recruited. The
aim of the study was finding a very efficient test able with a
high probability predicting response or non-response to cytotoxic
chemotherapy. For this purpose, we proposed different scenar-
ios for which a maximum of 50 patients in the derivation group
appears sufficient. Yet if this approach could be unsatisfying, other
trials are generally not presenting statistical considerations on the
sample size. Previous publications have underlined the risk of mis-
classifications according to the training-set sizes (28) and probably
thousands of samples (18) would be needed to construct list of
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Table 8 | mRNA signatures for response to chemotherapy (validation set): differential expression of the genes found in the signatures between
responders and non-responders.
Variable Non-responders (n=12) Responders (n=9) p (t -Test) p (Wilcoxon)
Mean ∆CT SD Mean ∆CT SD
β-ACTINASTHE REFERENCE GENE
FCN1 1.0017325 1.5452500 −0.3936098 2.0563888 0.09 0.16
RNF168 −5.0100427 1.2120509 −5.7443545 1.2098927 0.19 0.18
KRT16 −1.6581380 2.5237281 −0.4743034 3.2727341 0.36 0.38
SEMA3D 4.5458862 2.5837169 5.2979321 2.1402825 0.49 0.55
ULBP2 1.7438450 2.1160217 0.8658941 3.2716446 0.46 0.65
HPRTASTHE REFERENCE GENE
FCN1 5.6594930 2.1299628 4.3520158 2.8689951 0.24 0.35
RNF168 −0.3522822 0.8420686 −0.9987289 0.5571078 0.06 0.10
KRT16 2.9996225 2.2686257 4.2713223 2.4994064 0.24 0.25
SEMA3D 9.2036467 2.6198815 10.0435577 2.3809662 0.46 0.51
ULBP2 6.4016054 1.6569804 5.6115197 2.3782401 0.38 0.42
Table 9 | Comparison between responders and non-responders of the
expression of the two miRNAs contained in the predictive signature,
in the derivation and the validation sets.
Derivation set
(N =38)
P -value
(Wilcoxon)
No response
(N =21)
Response
(N =16)
miR375
Mean±STD 5.2±2.2 7.1±1.8 0.01
Median (min–max) 5.8 (−0.5–7.9) 7.3 (4.2–9.8)
miR149
Mean±STD 7.2±1.4 4.8±1.8 <0.001
Median (min–max) 6.5 (5.0–9.5) 4.8 (1.8–7.8)
Validation set
(N =22)
P -value
(Wilcoxon)
No response
(N =13)
Response
(N =9)
miR375
Mean±STD 3.8±1.7 2.3±2.3 0.07
Median (min–max) 2.8 (2.0–6.6) 1.7 (−0.2–7.6)
miR149
Mean±STD 5.4±1.7 4.2±1.2 0.11
Median (min–max) 5.3 (1.8–7.2) 4.3 (2.4–5.8)
The mean and median expression of the miRNAs are expressed in ∆CT values.
STD, standard deviation
genes with strong statistical validity and reproducible results. This
seems unrealistic when considering the major costs of microar-
rays and the difficulties in recruiting prospectively patients and
samples in translational research in lung cancer. This study can
only be achieved with an impressive grant from the first Belgian
Cancer Plan. Further, to achieve recruitment of enough patients
Table 10 | miRNA signatures for prediction of response to
chemotherapy and of survival (validation set): differential expression
according to the ∆CT values between the derivation and validation
sets.
Derivation
set (N =38)
Validation
set (N =22)
p (Wilcoxon)
miRNAs FOR RESPONSE
miR375
Mean±STD 6.1±2.2 3.2±2.0 <0.001
Median (min–max) 6.2 (−0.5–9.8) 2.7 (−0.2–7.6)
miR149
Mean±STD 6.0±2.0 4.9±1.6 0.03
Median (min–max) 6.2 (1.8–9.5) 5.2 (1.8–7.2)
miRNAs FOR OVERALL SURVIVAL
miR200c
Mean±STD 1.1±2.7 −0.7±1.0 <0.001
Median (min–max) 0.6 (−1.1–16.1) −0.9 (−2.7–1.7)
miR29c
Mean±STD 5.5±1.1 1.5±0.7 <0.001
Median (min–max) 5.6 (2.5–7.0) 1.4 (0.2–3.0)
miR424
Mean±STD 13.7±2.6 6.3±1.5 <0.001
Median (min–max) 13.5 (8.6–18.3) 6.1 (4.3–9.7)
miR124a
Mean±STD 16.0±3.0 7.4±1.4 <0.001
Median (min–max) 18.0 (9.3–18.8) 7.8 (4.0–9.4)
The mean and median expression of the miRNAs are expressed in ∆CT values.
STD, standard deviation.
for transcriptomic analyses, we had to register 300 patients dur-
ing a 4-year period of whom only 20% can be assessed both for
response and transcriptomic analyses, most of them because no
adequate tumor sample can be obtained during bronchoscopy.
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When discussing about the number of patients to be recruited in
such trials (18), this will be a major limiting factor for further
studies.
Another problem is the absence of distinction in our analyses
between the tumor and its microenvironment. This could be a
factor of discrepancy between the derivation and validation sets
that cannot be approached by the case-mix evaluation using con-
ventional clinical variables. According to the technique we used,
the whole biopsy was directly lysed in Tripure, including both
these components. Microdissection could be an option to avoid
this problematic that cannot be done in the present setting at risk
of degrading RNA by rapid activation of cell RNAses in those
very small biopsies. We previously used successfully this tech-
nique of extemporaneous treatment of the biopsy that we were
able to reproduce in the present study (29). We can further dis-
cuss the interest in the content of the signature. For predictive or
prognostic purposes, it may be possible that the genes, by them-
selves, contained in the signatures have limited importance (30),
while this is not the case if the research is dealing with assess-
ment of biological cancer behavior, provided that the signature
is reproducible in any situation. We limited the risk of additional
contamination by other tissues by restricting the eligible biop-
sies to tumors accessible by conventional bronchoscopy, avoiding
contamination by blood, skin, or muscle in case of percutaneous
lung biopsy or inclusion of other tissues depending on metasta-
tic sites (liver, nodes . . .). For the latter, at the time we designed
the study, we did not have data regarding bio-equivalence between
primary tumor and metastases, another reason why biopsies from
metastatic sites were not considered.
A third limitation is related to the reference genes used for
RT-qPCR normalization. In the second set, we decided using two
genes, HPRT (as in the derivation set) and β-actin, as we observed
for HPRT differential expression between responders and non-
responders. This was ultimately the case with β-actin. We con-
firmed that without normalization for these reference genes, the
ones contained in the signatures were not differentially expressed
in the validation set (data not shown). Other authors have yet pub-
lished on the limited sensitivity of various reference genes in lung
cancer samples, due to nucleic acid degradation and that “stably
expressed reference genes for normalization of gene expression
data using RT-qPCR have not been identified” (31).
Based on the literature data and the results of our study, high
throughput techniques have probably a limited usefulness for clin-
ical application. According to the efficiency of targeted therapies,
we have to evaluate if specific genetic abnormalities could have
potential predictive or prognostic implications as suggested by
meta-analyses. The evolution of sequencing allowing multiple
evaluations of specific targets on the same sample is opening new
options for future translational research.
This academic prospective translational study looking at the
interest of biological signatures for predicting chemosensitivity
and for prognostic purpose in advanced and metastatic NSCLC did
not reach its primary objective of validating biological signatures
either at mRNA or miRNA levels. According to the available litera-
ture, the role of high throughput techniques remains questionable
due to their lack of reproducibility. Signatures derived from these
analyses should not be anymore considered in absence of external
validation in independent groups of patients with identical clinical
characteristics and treatments.
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